Newly developed retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is creating considerable buzz within the weight loss community. Early clinical studies have shown impressive reductions in overall size and gains in physiological markers for patients with overweight. Scientists believe this unique approach has the potentia